MAP2K7 and acute lymphoblastic leukemia: Furthermore, we have shown that B-ALL cells harboring this mutation are sensitive to MEK inhibitors and offer a novel precision medicine target in the context of relapsed/refractory B-ALL for NF-1 patients.